SLC5A2 and chronic kidney disease: No significant benefit was observed in composite kidney outcomes compared with SGLT2 inhibitors alone.<h4>Conclusion</h4>Combining finerenone with SGLT2i may improve survival and reduced risks of MACEs and MAKEs compared with finerenone monotherapy in patients with diabetic CKD.